Omega 3 Fatty Acid Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Omega-3 Fatty AcidsPediatric Bipolar DisorderAdolescent Bipolar DisorderMagnetic Resonance Spectroscopy Imaging
Interventions
DIETARY_SUPPLEMENT

Omega-3 Fatty Acid

600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.

OTHER

Placebo

placebo pill of the same size, color, and shape as the dietary supplement.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Mayo Clinic

OTHER